{"id":"W3025022288","doi":"10.1056/nejmoa1915745","title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":7245,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Bayer Yakuhin; Eli Lilly Japan; Chugai Pharmaceutical; Novartis Pharma; Genentech; Sirtex Medical; Ipsen; Dainippon Sumitomo Pharma; Yakult Honsha; Gilead Sciences; Servier; Advanced Accelerator Applications; Teijin Pharma; Otsuka Pharmaceutical; Eisai; BeiGene; Cisco Systems; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Taiho Pharmaceutical; EA Pharma Co., Ltd.; Baxalta; Bayer HealthCare; Exelixis; Sanofi; Amgen; Pfizer; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Bevacizumab; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Carcinoma; Cancer; Chemotherapy; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001356775,0.0002577261,0.001073246,0.0004179536,0.0000928477,0.0002938347,0.0002409105,0.0002188987,0.001128419],"category_scores_gemma":[0.002312043,0.0001406308,0.0005728842,0.0003349961,0.0002086651,0.0002671288,0.0002967018,0.000670974,0.0001462244],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006171677,"about_ca_system_score_gemma":0.0004320209,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004551534,"about_ca_topic_score_gemma":0.001366766,"domain_scores_codex":[0.9995183,0.0002830095,0.00004392248,0.00003992164,0.00008087314,0.00003393516],"domain_scores_gemma":[0.9989789,0.0004393821,0.000326086,0.00003270435,0.00006876396,0.0001542696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3453617,0.003786851,0.0824589,0.004170801,0.005157271,0.001012755,0.0001788885,0.007417771,0.0208927,0.0004779793,0.002972503,0.5261119],"study_design_scores_gemma":[0.2358995,0.3781402,0.3114242,0.001076099,0.00897015,0.007720458,0.0002761238,0.01842158,0.01723322,0.001707351,0.01902968,0.0001013889],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9655519,0.0316379,0.0007154872,0.0007104563,0.0001243151,0.0001475276,0.0001214005,0.00003959707,0.0009512987],"genre_scores_gemma":[0.9950171,0.004040644,0.0003484301,0.0001218877,0.00008877843,0.00005923741,0.0001638334,0.000003561132,0.0001565719],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001356775,"threshold_uncertainty_score":0.007175446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0791161146425367,"score_gpt":0.264622043496366,"score_spread":0.1855059288538293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}